Home » Posts tagged with » China
Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818

Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818

Chinese pharma company Kangpu Biopharmaceuticals said that it has wrapped up the first-in-human phase 1 clinical trial of CRL4-CRBN modulator KPG-818 in the US. KPG-818 is being developed for the treatment of systemic lupus erythematosus (SLE) or hematological malignancies. The single ascending dose (SAD) randomized, double-blind, placebo-controlled study assessed the safety, tolerability, and pharmacokinetics of […]

CMAB Biopharma, BJ Bioscience join forces for bi-functional antibody BJ-005

CMAB Biopharma (Suzhou), a pure-play biologics CDMO, and BJ Bioscience have signed an agreement for the development and manufacturing of a bi-functional antibody called BJ-005 as the first initiative in an exclusive collaboration. As per the terms of the agreement, CMAB will offer a complete range of CMC research and manufacturing services that address the […]

Continue reading …
Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506

Chinese biotech company Bio-Thera Solutions has started dosing in a phase 1 clinical trial to study the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Janssen Biotech’s Simponi (golimumab). The early-stage clinical study is a randomized two-arm, parallel-group trial that will have nearly 182 healthy volunteers. Each of the patients will be subjected to […]

Continue reading …
NKF to invest $95m in US generic injectables company Meitheal

Pharma acquisition news : Hong Kong King-Friend Industrial Company, a subsidiary of Chinese manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF), has agreed to increase its stake in US generic injectables company Meitheal Pharmaceuticals for $95 million. Following the completion of the transaction, which is likely to be in Q4 2019, NKF will have a majority stake […]

Continue reading …
Boston Scientific to be distributor of Endologix products in China

US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China. The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also […]

Continue reading …
Gilead Sciences announces Biktarvy China approval for HIV-1

Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]

Continue reading …
Vitruvias, Sinotherapeutics launch antiarrhythmic drug Rythmol SR in US

US finished-dose generic drug company Vitruvias Therapeutics and Chinese pharma company Sinotherapeutics have announced the US launch of a bioequivalent FDA-approved version of antiarrhythmic drug Rythmol SR, known generically as propafenone hydrochloride. Rythmol SR, which is an oral administered drug, is supplied in extended-release capsules of 225, 325 and 425 mg. The antiarrhythmic drug is […]

Continue reading …
Chinese pharma companies to evaluate combo therapy in colorectal cancer

Chinese pharma companies Innovent Biologics and Shenzhen Chipscreen Biosciences have agreed to evaluate their respective drugs as combination therapy in advanced colorectal cancer. As per the agreement, Innovent’s Tyvyt (sintilimab injection) and IBI305 – a proposed biosimilar of Roche’s cancer drug bevacizumab will be evaluated in combination with Chipscreen Biosciences’ Chidamide. Tyvyt is a fully […]

Continue reading …
Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China

Samsung Bioepis, a South Korean biopharma company, has signed a licensing agreement with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in China. The agreement covers Samsung Bioepis’ various biosimilar candidates like SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, and also SB3, a biosimilar candidate referencing HERCEPTIN 3 […]

Continue reading …
InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma

InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and Taiwan to Betta Pharma, in a deal worth more than RMB230 million ($33.44 million). The two Chinese pharma companies have forged a partnership to co-develop the drug in China. D-0316, which was discovered by InventisBio, […]

Continue reading …
Page 1 of 212